BioPharma Dive1 min read
saveCG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
comments(0)
5-min edit window · permanent after that